Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

60 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT07476170 2026-03-17

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

Not yet recruiting

14,000 enrolled

Breast Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05132582 2026-03-16

HER2CLIMB-05

654 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

120 enrolled

Triple Negative Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Active not recruiting

1,019 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06610539 2026-03-16

MAGProm

Recruiting

184 enrolled

Breast Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

416 enrolled

Triple Negative Breast Neoplasms

NCT06930859 2026-03-16

ELEGANCE

Recruiting

2,766 enrolled

Breast Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07085767 2026-03-16

OPERA-02

1,000 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07287098 2026-03-16

preEMBER

600 enrolled

Breast Neoplasms

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT07368998 2026-03-16

optINAVO

Phase 2 Recruiting

80 enrolled

Breast Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05677308 2026-03-13

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Completed

61 enrolled

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

55 enrolled

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT06312176 2026-03-13

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06393374 2026-03-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

BreastGastrointestinalHead & Neck

Triple Negative Breast Neoplasms

NCT06681233 2026-03-13

Feasibility Study of CBCT for IGRT in Cancer Patients

Phase NA Recruiting

50 enrolled

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Urogenital Neoplasms

NCT06745804 2026-03-13

Study of 68Ga-R10602

Phase 1 Recruiting

36 enrolled

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer

NCT06841354 2026-03-13

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

90 enrolled

BreastGastrointestinalSarcomaThoracic

Breast Neoplasms

NCT07261631 2026-03-13

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Phase 1 Recruiting

180 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

25 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05417594 2026-03-12

CERTIS1

BreastCNSGastrointestinalGenitourinaryGynecologic

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06085833 2026-03-12

ANGEL

Phase NA Recruiting

2,706 enrolled